Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.
Call it a big day for Roche at the FDA, as the drug giant picked up two critical approvals on Thursday.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.
In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.
New discount deals with cost watchdogs in England have breast cancer drugs from Pfizer and Novartis on more equal footing than in the U.S.
Rare disease biotech Ultragenyx has its first FDA nod in Mepsevii, an enzyme therapy expected to carry a high price to treat a tiny group of patients.
AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.
Bayer's consumer health ambitions have been frustrated by declining U.S. sales, and now it's shaking up management to get the unit back on track.
Johnson & Johnson's Xarelto has more results to back up its artery disease case—and help it extend its indication lead over the competition.